{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:17:00Z","timestamp":1794277020332,"version":"4.9.0"},"reference-count":17,"publisher":"American Association for Cancer Research (AACR)","issue":"16","funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Messenger RNA (mRNA)-2752, a lipid nanoparticle\u2012encapsulated, mRNA-based therapeutic encoding OX40L, interleukin 36\u03b3 (IL-36\u03b3), and IL-23, has demonstrated modulation of the tumor microenvironment (TME) and antitumor efficacy in combination with immune checkpoint inhibitors (CPI) in CPI-resistant models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>In this phase I study (NCT03739931) of intratumoral mRNA-2752 monotherapy (arm A) or mRNA-2752 plus durvalumab (arm B) in advanced solid tumors, the primary objectives were safety, tolerability, determination of maximum tolerated dose (MTD), and objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors version 1.1 in CPI-resistant melanoma (arm B only).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 134 patients (arm A, n = 19 and arm B, n = 115), the MTD was not reached; a recommended dose for expansion of \u22648 mg was selected. Dose-limiting toxicities included two grade II cytokine-release syndrome events in arm B. Treatment-related adverse events (AE) were mostly grade I\/II; grade III mRNA-2752\u2013related AEs occurred in 1 patient (5.3%) in arm A and 29 patients (25.2%) in arm B. In the CPI-resistant melanoma cohort (n = 28), across doses, the confirmed ORR was 17.9% (95% CI, 6.1%\u201236.9%), and the disease control rate was 42.9% (95% CI, 24.5%\u201262.8%). Increased peripheral cytokine levels and sustained inflammatory responses in the TME were observed, particularly in patients with an objective response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>mRNA-2752 monotherapy or in combination with durvalumab demonstrated antitumor activity with manageable safety in patients with heavily pretreated, relapsed, or resistant solid tumors, particularly in patients with CPI-resistant melanoma. In addition, biomarker analyses demonstrated a sustained inflammatory response within the TME. Together, these findings support the investigation of mRNA-based therapeutics for patients with advanced cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-25-4643","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:53:03Z","timestamp":1779115983000},"page":"3493-3505","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipid Nanoparticle\u2013Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36\u03b3 plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors"],"prefix":"10.1158","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0497-9637","authenticated-orcid":false,"given":"Randy F.","family":"Sweis","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/024mw5h28","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Chicago 1 Section of Hematology\/Oncology, Department of Medicine, , Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"2Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-8421","authenticated-orcid":false,"given":"Adil","family":"Daud","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California San Francisco 3 Helen Diller Family Comprehensive Cancer Center, , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-3929","authenticated-orcid":false,"given":"Salomon M.","family":"Stemmer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01vjtf564","id-type":"ROR","asserted-by":"publisher"}],"name":"Rabin Medical Center 4 Davidoff Center, , Petach Tiqwa and Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8560-0440","authenticated-orcid":false,"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[{"name":"5Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-6577","authenticated-orcid":false,"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[{"name":"6Division of Oncology, and Clinical Research Institute at Rambam, Rambam Medical Center, and Ruth and Bruce Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-1627","authenticated-orcid":false,"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[{"name":"7Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-2364","authenticated-orcid":false,"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"8Drug Development Unit, Sarah Cannon Research Institute\/Florida Cancer Specialists, Sarasota, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-3818","authenticated-orcid":false,"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, One Clinical Research and Edith Cowan University, Perth, Western Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9201-2502","authenticated-orcid":false,"given":"Michael","family":"Abadier","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xm4wg91","id-type":"ROR","asserted-by":"publisher"}],"name":"Moderna, Inc. 10 Oncology Research and Clinical Development, Therapeutics and Oncology, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9249-9539","authenticated-orcid":false,"given":"Linh","family":"Van","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xm4wg91","id-type":"ROR","asserted-by":"publisher"}],"name":"Moderna, Inc. 10 Oncology Research and Clinical Development, Therapeutics and Oncology, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0947-726X","authenticated-orcid":false,"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xm4wg91","id-type":"ROR","asserted-by":"publisher"}],"name":"Moderna, Inc. 10 Oncology Research and Clinical Development, Therapeutics and Oncology, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-8899","authenticated-orcid":false,"given":"Khanh T.","family":"Do","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xm4wg91","id-type":"ROR","asserted-by":"publisher"}],"name":"Moderna, Inc. 10 Oncology Research and Clinical Development, Therapeutics and Oncology, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"11Massachusetts General Brigham Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2026081403102850800_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"2026081403102850800_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2026081403102850800_bib3","doi-asserted-by":"crossref","first-page":"926321","DOI":"10.1155\/2012\/926321","article-title":"Targeting costimulatory molecules to improve antitumor immunity","volume":"2012","author":"Capece","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"2026081403102850800_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026081403102850800_bib5","doi-asserted-by":"crossref","first-page":"1479483","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2024","journal-title":"Front Immunol"},{"key":"2026081403102850800_bib6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"2026081403102850800_bib7","doi-asserted-by":"crossref","first-page":"oyaf115","DOI":"10.1093\/oncolo\/oyaf115","article-title":"First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer","volume":"30","author":"Sullivan","year":"2025","journal-title":"Oncologist"},{"key":"2026081403102850800_bib8","doi-asserted-by":"crossref","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026081403102850800_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026081403102850800_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","article-title":"An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts","volume":"41","author":"Dousis","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026081403102850800_bib11","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"2026081403102850800_bib12","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","article-title":"Intratumoral immunotherapy for early-stage solid tumors","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026081403102850800_bib13","doi-asserted-by":"crossref","first-page":"S1236","DOI":"10.1016\/j.annonc.2024.08.2287","article-title":"LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti\u2013PD-1\u2013failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab","volume":"35","author":"Robert","year":"2024","journal-title":"Ann Oncol"},{"key":"2026081403102850800_bib14","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026081403102850800_bib15","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026081403102850800_bib16","doi-asserted-by":"crossref","first-page":"e000650","DOI":"10.1136\/jitc-2020-000650","article-title":"Durvalumab activity in previously treated patients who stopped durvalumab without disease progression","volume":"8","author":"Sheth","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026081403102850800_bib17","doi-asserted-by":"crossref","first-page":"641428","DOI":"10.3389\/fonc.2021.641428","article-title":"The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy","volume":"11","author":"Russell","year":"2021","journal-title":"Front Oncol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-4643\/3794775\/ccr-25-4643.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-4643\/3803906\/ccr-25-4643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/16\/3493\/3819904\/ccr-25-4643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/16\/3493\/3819904\/ccr-25-4643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:10:37Z","timestamp":1786691437000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/32\/16\/3493\/787320\/Lipid-Nanoparticle-Encapsulated-mRNA-2752-Encoding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":17,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,5,18]]},"published-print":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-4643","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.33252930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252912","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252921","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252900","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252927","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252906","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252903","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252915","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252909","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.33252918","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.8653758","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}